Navigation Links
New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution
Date:10/19/2009

BOSTON, Oct. 19 /PRNewswire/ -- There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change, e.g., before the disease has come and gone. In view of Replikins Ltd.'s demonstration that Replikins(TM) chemically synthesized vaccines produced in seven days can be effective, the company today proposed these new vaccines as a solution to the problem of these emerging diseases. Furthermore, it established WorldVaccines(TM), Ltd to test and distribute synthetic Replikins(TM) vaccines.

As the first batches of the biological H1N1 ("Swine Flu") vaccines reach consumers worldwide, seven months after the flu outbreak, this small biotech firm in Boston today announced that it has created the first truly synthetic influenza vaccine that targets the broad range of A influenza viruses including H1N1, H5N1, H9N2, and H3N2, which was shown to be effective against the H5N1 (Avian Flu) virus. TransFlu(TM) is the first truly synthetic cross-strain pan-influenza vaccine.

In an independent study published in the peer-reviewed journal Avian Diseases, the synthetic Replikins TransFlu(TM) vaccine was shown to be effective in decreasing infectivity and completely blocking excretion of LPAI H5N1 virus in chickens, permitting for the first time the possibility of blocking animal virus reservoir development, a major precursor of human disease.

Both TransFlu(TM) and Taura Syndrome Virus vaccines were manufactured in seven days; kilogram amounts could be made in a few weeks, rather than six to 12 months needed for biological vaccine production. The cost to produce the synthetic vaccine is also far less than the cost of current biological production methods. Given the demonstrated effectiveness and rapid availability, it appears inevitable that synthetic Replikins(TM) vaccines will eventually replace biological vaccines.

Further, until now, all influenza vaccines have been produced in biologically living cells. Whether whole virus or recombinant virus sections are reproduced in eggs, kidney, hamster, E.coli, or other cells, these living cells provide the obligatory contamination in the vaccine of thousands of unwanted immunogenic proteins, the potential for other virus contamination (viruses only reproduce in living cells), and the need for potentially toxic preservatives.

Over the last decade, Drs. Samuel and Elenore Bogoch have been developing vaccine-manufacturing methods that are non-biological, based on software algorithms designed to study virus structure, and organic chemistry. The new, completely synthetic Replikins(TM) Vaccine Technology1-4 targets a group of genomic peptides that they discovered and named Replikins(TM). These genomic peptides were found to be conserved in viruses cross-strain over decades, and to be related to rapid replication and epidemic outbreaks.

The centrality of the Replikins(TM) to influenza has been confirmed recently by the data of two independent groups, Harvard-CDC and Scripps-Crucell. Their findings demonstrate that inhibitory antibody lands on and binds selectively to the very peptides that the Drs. Bogoch have previously identified as Replikins(TM).

Three months to one year in advance of an outbreak, the related Replikins(TM) FluForecast(R) software warns of the oncoming emergent disease. This technology was recently validated when it successfully identified, a year in advance, the current H1N1 outbreak. The technology also defines the Replikins(TM) that need to be synthesized in the vaccine. Thus the Replikins(TM) structures, which make up both the newly discovered infectivity and lethality genes within the virus genome, provide the keys to both advance warning and synthetic vaccine production.

References:

1. Replikins.com. Replikins Press. 31 reports published by Replikins Ltd.

2. Bogoch, S. and Bogoch, E.S., Replikins: the Chemistry of Rapid Replication. Monograph. Begell House, New York, 2005.

3. Bogoch, S. et al., Replikins. Published patent applications and issued patents, US Patent Office, 2002-2009.

4. Jackwood, M. et al. Efficacy of a Replikin Peptide Vaccine Against Low Pathogenicity Avian Influenza H5 Virus. Avian Diseases, PublicationOnline,doi:10.1637/8892-042509-Res. Note.1; Hard copy Article In Press. July 2009.

Foundation for Research on the Nervous System and Replikins, Ltd., 36 The Fenway, Boston, MA 02215. http://www.replikins.com.

    Contact:

    John McKenney
    Replikins Ltd.
    jmckenney@replikins.com
    617-536-0220

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE Replikins Ltd.


'/>"/>
SOURCE Replikins Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
2. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
3. Venter Institute Scientists Create First Synthetic Bacterial Genome
4. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
5. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
6. The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems
7. RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
8. Synthetic Biology Importance in the 21st Century
9. Synthetic Biology: The Next Biotech Revolution Is Brewing
10. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
11. Synthetic Biology on the Rise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):